News & Updates
Filter by Specialty:

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
byAudrey Abella
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.